Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer ... Another potential rival - CG Oncology's retostimogene grenadenorepvec ...

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the ... Anktiva could also be on the way from CG Oncology, a recent Nasdaq debutante whose ...

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...